Cover Image

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Diabetes, Obesity and Metabolism
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post‐hoc analysis from a double‐blinded randomized controlled trial
by: Melissa‐Rosina Pasqua, et al.
Published: (2025)

Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial
by: Melissa‐Rosina Pasqua, et al.
Published: (2025)

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial
by: Massimo Nardone, et al.
Published: (2026)

Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( RACELINES ): A randomised, double‐blind trial
by: Michaël J. B. van Baar, et al.
Published: (2025)

Fotagliptin add‐on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double‐blind, placebo‐controlled, phase 3 trial
by: Nan Yu, et al.
Published: (2025)

Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, cross‐over trial
by: Bertrand Cariou, et al.
Published: (2025)

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
by: Da Hea Seo, et al.
Published: (2025)

Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial
by: Minji Sohn, et al.
Published: (2024)

Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial
by: Yingying Xiang, et al.
Published: (2024)

SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial
by: Didde Kidmose Kristensen, et al.
Published: (2024)

Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4
by: Vikas S. Sridhar, et al.
Published: (2024)

Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
by: Leili Gao, et al.
Published: (2024)

Efficacy and safety of intragastric expandable oral capsules in adults with overweight or obesity: A randomized, double‐blind, placebo‐controlled trial
by: Difei Lu, et al.
Published: (2024)

Efficacy and safety of imeglimin add‐on to DPP ‐4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double‐blind FAMILIAR trial
by: Kohei Kaku, et al.
Published: (2025)

Retagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
by: Lixin Guo, et al.
Published: (2024)

Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
by: Stefan R. Bornstein, et al.
Published: (2024)

A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
by: Panpan Xie, et al.
Published: (2024)

A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
by: Soo Lim, et al.
Published: (2024)

Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study
by: In‐Kyung Jeong, et al.
Published: (2024)

Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV
by: Vikas S. Sridhar, et al.
Published: (2024)

Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
by: Ayodele Odutayo, et al.
Published: (2024)

Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)
by: Weiping Jia, et al.
Published: (2026)

Association between patient‐reported eating behaviours and weight change: Secondary analyses of a randomized, double‐blind trial comparing retatrutide and placebo in people with obesity or overweight
by: Chisom Kanu, et al.
Published: (2025)

Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial
by: Manu V. Chakravarthy, et al.
Published: (2025)

Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial
by: Fei Gao, et al.
Published: (2026)

Biomarkers for cardiovascular–kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment
by: Kevin Yau, et al.
Published: (2025)

A biweekly DPP ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial
by: Qinghua He, et al.
Published: (2024)

A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN )
by: Tomoaki Morioka, et al.
Published: (2024)

Semaglutide and MASH resolution: A pooled analysis of recent trials
by: Alaa Abdrabou Abouelmagd, et al.
Published: (2025)

EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes ; randomized, placebo‐controlled, double‐blind, multicentre trial ( CANNA study)
by: Ji Eun Jun, et al.
Published: (2025)

Acute effects of GIP and GLP ‐1 receptor antagonism in totally pancreatectomized individuals: A randomized double‐blind, placebo‐controlled crossover study
by: Liva S. L. Krogh, et al.
Published: (2025)

Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial
by: Tobias Kühne, et al.
Published: (2024)

Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
by: Amir Razaghizad, et al.
Published: (2024)

Empagliflozin for the preservation of beta‐cell function in women with recent gestational diabetes: A randomized placebo‐controlled trial
by: Shamini Murugavel, et al.
Published: (2025)

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
by: Lauren Wilson, et al.
Published: (2026)

Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme
by: Pedro Marques, et al.
Published: (2024)

Impact of stepwise diabetes technology advances in older adults with type 1 diabetes: A systematic review and meta‐analysis of randomised trials
by: Mengyun Lei, et al.
Published: (2025)

Glucose‐dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes—A randomised placebo‐controlled study
by: Bjørn Hoe, et al.
Published: (2025)

Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
by: Yao Wang, et al.
Published: (2024)

Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial
by: Qian Ren, et al.
Published: (2024)